Back to Search
Start Over
Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia.
- Source :
-
Advances in Hematology . 2012, p1-13. 13p. 1 Chart, 3 Graphs. - Publication Year :
- 2012
-
Abstract
- B-cell chronic lymphocytic leukaemia (B-CLL) remains an incurable disease due to the high risk of relapse, even after complete remission, raising the need to control and eliminate residual tumor cells in long term. Adoptive T cell therapy with genetically engineered specificity is thought to fulfil expectations, and clinical trials for the treatment of CLL are initiated. Cytolytic T cells from patients are redirected towards CLL cells by ex vivo engineering with a chimeric antigen receptor (CAR) which binds to CD19 on CLL cells through an antibody-derived domain and triggers T cell activation through CD3ΞΆ upon tumor cell engagement. Redirected T cells thereby target CLL cells in an MHC-unrestricted fashion, secret proinflammatory cytokines, and eliminate CD19+ leukaemia cells with high efficiency. Cytolysis of autologous CLL cells by patient's engineered T cells is effective, however, accompanied by lasting elimination of healthy CD19+ B-cells. In this paper we discuss the potential of the strategy in the treatment of CLL, the currently ongoing trials, and the future challenges in the adoptive therapy with CAR-engineered T cells. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 16879104
- Database :
- Academic Search Index
- Journal :
- Advances in Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 86936922
- Full Text :
- https://doi.org/10.1155/2012/595060